Research
Hormonal
Tirzepatide has demonstrated superior efficacy in promoting weight loss and maintaining a healthy body weight compared to traditional incretin therapies.
Tirzepatide may be a more effective option for weight management in patients with obesity.
StrongSupportsmedium confidence
Tirzepatide, a dual incretin receptor agonist, has demonstrated superior efficacy in promoting weight loss and maintaining a healthy body weight.
Why this rating
The claim is based on a review of selected articles and reports, indicating a strong basis for the assertion.
Source
TIRZEPATIDE - A NEW ERA IN OBESITY TREATMENT? A REVIEW OF THE CURRENT STATE OF KNOWLEDGE
Adam Solarz et al. · International Journal of Innovative Technologies in Social Science · 2025
DOI 10.31435/ijitss.4(48).2025.4143
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →